Abstract
The tolerance and antitumor activity of Lonidamine administered alone and in combination with other anticancer agents were studied. Myalgia was the most frequent side effect; there were no changes in the hematological parameters attributable to Lonidamine administration. 1 partial response out of the 16 patients treated with Lonidamine alone was observed.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols*
-
Carcinoma, Small Cell / drug therapy*
-
Carcinoma, Squamous Cell / drug therapy*
-
Double-Blind Method
-
Female
-
Humans
-
Indazoles / adverse effects
-
Indazoles / therapeutic use*
-
Male
-
Middle Aged
-
Muscles / drug effects
-
Pyrazoles / therapeutic use*
-
Random Allocation
Substances
-
Indazoles
-
Pyrazoles
-
lonidamine